Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus

Yamada, Yusuke; Nozawa, Kazuki; Nakano, Soichiro; Mitsuo, Yukiko; Hiruma, Kaori; Doe, Kentaro; Sekigawa, Iwao; Yamanaka, Kenjiro; Takasaki, Yoshinari

doi:10.3109/14397595.2015.1123345

Cited by 17 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAP -2 regulates the nucleation and stabilization of microtubules, organelle transport protein kinases that are involved in signal transduction 55) . In a study by Yamada et al, 33.3% of NPSLE patients tested positive for anti -MAP -2 in the CSF 54) . Williams also reported that 17% of SLE patients had anti -MAP -2 in contrast to 4% of neurologic injury/disease control patients 56) .…”

Section: Antimicrotubuleassociated Protein 2 Antibodies (Anti -Map -2)mentioning

confidence: 93%

See 1 more Smart Citation

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers

Sato

Temmoku

Fujita

et al. 2020

FJMS

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs, including the central nervous system. Neuropsychiatric SLE (NPSLE) is a severe and potentially fatal condition. Several factors including autoantibodies have been implicated in the pathogenesis of NPSLE. However, definitive biomarkers of NPSLE are yet to be identified owing to the complexity of this disease. This is a major barrier to accurate and timely diagnosis of NPSLE. Studies have identified several autoantibodies associated with NPSLE ; some of these autoantibodies are well investigated and regarded as symptomspecific. In this review, we discuss recent advances in our understanding of the manifestations and pathogenesis of NPSLE. In addition, we describe representative symptomspecific autoantibodies that are considered to be closely associated with the pathogenesis of NPSLE.

show abstract

Section: Antimicrotubuleassociated Protein 2 Antibodies (Anti -Map -2)mentioning

confidence: 93%

“…MAP -2 is one of the abundant groups of cytoskeletal components predominantly expressed in neurons 54) . MAP -2 regulates the nucleation and stabilization of microtubules, organelle transport protein kinases that are involved in signal transduction 55) .…”

Section: Antimicrotubuleassociated Protein 2 Antibodies (Anti -Map -2)mentioning

confidence: 99%

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers

Sato

Temmoku

Fujita

et al. 2020

FJMS

View full text Add to dashboard Cite

show abstract

“…reported that CSF anti-ribosomal P titer was significantly higher in NPSLE patients with anti-microtubule-associated protein-2 (MAP-2) Ab than in those without MAP-2 Ab or non-NSPLE patients. 32 They did not, however, examine the combined effect of both auto Abs. We also measured anti-ribosomal P Ab in CSF; however, the anti-ribosomal P positivity was low (8.2%) for a relevant statistical analysis.…”

Section: Discussionmentioning

confidence: 99%

Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus

Kondo-Ishikawa

Fujii

Ishigooka

et al. 2020

Lupus

View full text Add to dashboard Cite

Background Autoantibodies (auto Abs) and inflammatory mediators (IMs) in cerebrospinal fluid (CSF) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). It is suggested that anti- N-methyl D-aspartate receptor NR2 subunit (NR2) Ab can develop NP manifestation after blood–brain barrier (BBB) abruption. We also reported the association between NPSLE and CSF anti-U1RNP Ab. In the present study, combined effects of CSF anti-NR2 and anti-U1RNP Abs on IMs in patients with NPSLE were examined. Methods CSF samples were collected from 69 patients with NPSLE and 13 non-NPSLE controls. CSF anti-NR2 and anti-U1RNP Abs were determined using ELISA. Levels of IL-6, IL-8, and monokine induced by IFN-γ (MIG) in CSF were measured by quantitative multiplex cytokine analysis. Results CSF IL-6 levels were higher in CSF anti-NR2-positive than in CSF anti-NR2-negative patients ( p = 0.003) and non-NPSLE controls ( p = 0.015) and were positively correlated with anti-NR2 titer ( r = 0.42). CSF IL-8 levels were higher in CSF anti-U1RNP-positive than in CSF anti-U1RNP-negative patients ( p = 0.041). CSF MIG levels were more elevated in CSF anti-NR2-positive ( p = 0.043) and anti-U1RNP-positive patients ( p = 0.029) than in non-NPSLE controls. Additionally, in double positive (DP; both anti-NR2 and U1RNP Ab positive) group, CSF IL-6 and MIG levels were significantly higher than in the double negative (DN; both anti-NR2 and U1RNP Ab negative) group. However, combined effect of both Abs on IM elevation and clinical manifestation was not clear. Conclusions CSF anti-NR2 and anti-U1RNP Abs have different effects on the elevation of CSF IM levels in patients with NPSLE. Additional effect of anti-U1RNP Abs on anti-NR2 Ab-mediated NP manifestation, however, was not recognized in our study.

show abstract

“…Significantly higher anti-microtubule-associated protein-2 (anti-MAP-2) antibody titers were discovered in the CSF of patients with NPSLE compared to the CSF of non-NPSLE controls. Anti-MAP-2 antibody prevalence was 33.3% in NPSLE ( 146 ).…”

Section: Disease Markers For Neuropsychiatric Sle (Npsle) and Sle With Other Comorbiditiesmentioning

confidence: 98%

Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus

et al. 2022

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease which can affect various tissues and organs, posing significant challenges for clinical diagnosis and treatment. The etiology of SLE is highly complex with contributions from environmental factors, stochastic factors as well as genetic susceptibility. The current criteria for diagnosing SLE is based primarily on a combination of clinical presentations and traditional lab testing. However, these tests have suboptimal sensitivity and specificity. They are unable to indicate disease cause or guide physicians in decision-making for treatment. Therefore, there is an urgent need to develop a more accurate and robust tool for effective clinical management and drug development in lupus patients. It is fortunate that the emerging Omics have empowered scientists in the discovery and identification of potential novel biomarkers of SLE, especially the markers from blood, urine, cerebrospinal fluids (CSF), and other bodily fluids. However, many of these markers have not been carefully validated for clinical use. In addition, it is apparent that individual biomarkers lack sensitivity or specificity. This review summarizes the sensitivity, specificity and diagnostic value of emerging biomarkers from recent studies, and discusses the potential of these markers in the development of biomarker panel based diagnostics or disease monitoring system in SLE.

show abstract

Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus

Abstract: Anti-MAP-2 antibodies could be detected in the CSF of 33.3% of patients with NPSLE, and its presence was highly specific for NPSLE. We propose that CSF anti-MAP-2 antibodies are a novel and useful diagnostic biomarker for NPSLE.

Cited by 17 publications

References 36 publications

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers

Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers

Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus

Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus

Contact Info

Product

Resources

About